Gyre Therapeutics, Inc. (GYRE) Cash Flow Statement

In the most recent quarter, operating cash flow of negative $16.7M was significantly worse than the net loss of $10.6M, indicating that the core business is consuming cash at a rate exceeding its reported accounting losses. This deterioration in cash conversion quality, especially when compared to the positive OCF generated in earlier profitable quarters, suggests the company's cost structure is now generating real cash deficits, not just paper losses.

The FCF trajectory shows a clear and concerning shift from intermittent positive quarters to a deepening cash burn. The negative FCF margin of -61.9% in the latest quarter is far worse than the -28.0% seen in 2024Q2, indicating that the cash burn is accelerating relative to revenue. This trend implies the company is not on a path to self-funding and will likely require external capital to sustain operations.

The large, inconsistent swings in working capital, such as the -$9.5M drag in 2025Q4 followed by the +$9.5M benefit in 2026Q1, suggest potential lumpiness in collections or payables timing that obscures the underlying operational cash trend. While the recent positive contributions have helped, they are not sustainable and mask the severity of the core operating cash burn.

The consistently low CapEx/Rev ratio, peaking at only 5.8% in 2024Q2, confirms Gyre operates an asset-light model typical of a biotech focused on licensing or royalties. However, the fundamental problem is not capital intensity but the massive operating expense burden, as even zero CapEx would not make the business cash-flow positive at the current operating loss level.

The complete absence of shareholder returns or strategic acquisitions (aside from a minor $6K outflow in 2026Q1) indicates management is conserving all available liquidity to fund operations. This lack of deployment is a rational response to the cash burn trajectory but offers no offset to the value erosion from ongoing losses.